Skip to main content
S&P 5007,650.50+0.17%DOW51,682.64-0.18%NASDAQ26,522.54+0.39%BTC$81,273.00+6.27%ETH$2,618.91+7.14%GOLD$4,415.90+0.37%OIL$95.47-1.81%
Smart Investors Daily
AL

NYSE · ALNY

Alnylam Pharmaceuticals, Inc.

Healthcare · Biotechnology

$239.56

Down-$5.95 (-2.42%)

Updated Sep 20, 2026, 11:55 AM

SID Score

4.7/10

Composite research score

Smart Money

58/100

Neutral

Market cap
44.15B
P/E ratio
140.31
Dividend yield
0.00%
52-week range
$197.81 – $495.55
Volume
2.76M
Avg. volume
1.54M

Price performance

ALNY price history

1M range · 19 trading sessions · Daily adjusted prices

ALNY closed at $239.56 after 19 trading sessions, up 1.50% for the selected period.

Last close
$239.56
Period change
+1.50%
Period low
$236.01
Period high
$267.40
Daily close
View OHLC price history
ALNY OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Sep 18, 2026$246.41$246.49$238.51$239.562.76M
Sep 17, 2026$242.60$245.63$239.50$245.511.01M
Sep 16, 2026$239.50$242.24$236.00$239.36853.9K
Sep 15, 2026$246.99$247.425$237.44$238.272.18M
Sep 14, 2026$250.165$252.79$244.18$249.99997.23K
Sep 11, 2026$248.05$254.08$246.01$248.681.18M
Sep 10, 2026$256.68$256.68$246.42$247.511.63M
Sep 9, 2026$257.07$261.98$253.275$258.001.43M
Sep 8, 2026$259.00$272.08$254.005$260.102.01M
Sep 4, 2026$258.58$266.85$258.02$266.111.43M
Sep 3, 2026$265.94$271.19$261.54$264.501.71M
Sep 2, 2026$246.48$269.94$246.48$267.403.29M
Sep 1, 2026$242.398$248.13$238.00$246.111.94M
Aug 31, 2026$235.94$243.02$233.3306$240.691.64M
Aug 28, 2026$224.465$239.08$223.61$237.101.85M
Aug 27, 2026$236.56$238.00$230.455$236.561.29M
Aug 26, 2026$238.54$242.89$236.60$239.001.12M
Aug 25, 2026$236.56$240.67$235.411$240.081.58M
Aug 24, 2026$235.83$237.905$228.59$236.012.14M

Latest ALNY news

The latest Smart Investors Daily articles mentioning ALNY.

Stock researchCompany · Overview

ALNY research

Overview

Company profile and research snapshot.

Company profile

Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway in cells that enables sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
$495.36
Implied upside
—
Analysts
20
ALNY recent ratings
DateFirmRatingTarget
Sep 8, 2026JefferiesHold—
Sep 2, 2026HC Wainwright & Co.Buy—
Aug 19, 2026BMO CapitalOutperform—
Aug 14, 2026Wells FargoEqual-Weight—
Aug 4, 2026HC Wainwright & Co.Buy—
Open full forecast

News briefing

Generated Sep 20, 2026, 11:03 AM

Why Is ALNY Down Today?

Alnylam Pharmaceuticals shares declined 2.42% today amid a broader market discussion of the RNA interference therapeutics landscape and the company's ongoing clinical pipeline developments. While the recent coverage is neutral in tone, the stock weakness may reflect investor cautiousness ahead of key pipeline milestones or broader biotech sector headwinds.

    Bottom line: Alnylam's 2.4% decline appears to reflect a lack of immediate positive catalysts rather than negative news, with the company's pipeline development proceeding as expected. Investors should focus on upcoming Zilebesiran clinical data and regulatory progress as key near-term catalysts, while remaining mindful of execution risks inherent in clinical-stage biotech investments.

    Yahoo · Sep 18, 2026

    RNA Interference Therapeutics Market Outlook 2026-2035 - Featuring Profiles of Alnylam Pharmaceuticals, Arrowhead Pharmaceuticals, and Silence Therapeutics

    RNAi Therapeutics Expand on Precision Medicine Demand, Advanced Subcutaneous Delivery and Growing Rare Disease ApplicationsDublin, Sept. 18, 2026 (GLOBE NEWSWIRE) -- "RNA Interference Therapeutics Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2026-2035" has been added to ResearchAndMarkets.com's offering. Global RNA Interference Therapeutics Market to Reach USD 31.4 Billion by 2035 The global RNA interference therapeutics market was valued at USD 4.2 billion in 2025 a

    Yahoo · Sep 15, 2026

    Is Alnylam (ALNY) Quietly Repricing Its RNAi Risk Profile Amid Oligonucleotide Market Optimism?

    Alnylam Pharmaceuticals recently presented at Wells Fargo’s 21st Annual Healthcare Conference in Boston and Morgan Stanley’s 24th Annual Global Healthcare Conference in New York, highlighting its RNA interference portfolio to investors and industry peers. These appearances coincided with a very large projected expansion of the global oligonucleotide therapeutics market to US$72.10 billions by 2035, underscoring Alnylam’s positioning as a key RNA-based medicines innovator. We’ll now examine...

    AI research layers

    Interpretive context generated from the platform’s current data sources.

    No results

    AI research layers have not been published yet.

    Featured By